Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System

Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System

We analyzed thromboembolic events, recognized (AESIs), with cyclin-dependent kinase (CDK)4/6 inhibitors, using the Food and Drug Administration adverse event reporting system. Methods: Thromboembolic events were characterized in terms of spectrum [venous and arterial thromboembolism (VTE; ATE)] and...

Full description

Bibliographic Details
Main Authors: Emanuel Raschi, Michele Fusaroli, Andrea Ardizzoni, Elisabetta Poluzzi, Fabrizio De Ponti
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Cancers
Subjects:
cyclin-dependent kinase (CDK) 4/6 Inhibitors
thromboembolism
pharmacovigilance
FAERS
signal
Online Access:https://www.mdpi.com/2072-6694/13/8/1758

Internet

https://www.mdpi.com/2072-6694/13/8/1758

Similar Items